Mandos Health

Mandos Health is a biopharmaceutical company dedicated to further developing VTS-270 for Niemann-Pick Type C, an extremely rare genetic disorder that affects the body's ability to metabolize cholesterol and lipids within cells. Niemann-Pick Type C disease impacts the brain, nerves, liver, spleen, bone marrow, and lungs, and currently, there are no treatments approved by the U.S. Food and Drug Administration.